The great burqa/niqab/hijab debate

To ban or not to ban? And what to ban?

From the Independent:

The parliamentary leader of the ruling French party is to put forward a draft law within two weeks to ban the full-body veil from French streets and all other public places.

Extreme? Right-wing? The article continues:

Some senior figures on the left have supported the idea of a legal ban. So has Fadela Amara, a left-wing campaigner for the rights of Muslim women who entered Mr Sarkozy's government in 2007 as minister for urban development.

Most moderate Islamic leaders have sharply criticised the burqa but suggested that it was such a limited phenomenon in France that legislation was unnecessary and might alienate moderate Muslims.

The burqa, per se, is an Afghan tradition allowing a woman only a narrow gauze-covered eye-opening. It is little found in France. The Arab equivalent, the niqab, which has a narrow opening at eye-level, is only slightly more common.

A study by the French internal security services last year suggested that the total number of women wearing both types of full-body veil in France was around 2,000 -- out of a total French population of adult, Muslim women of about 1,500,000.

Two questions immediately come to mind:

1) In the middle of the worst economic crisis in living memory, how can France's ruling conservative party justify focusing its legislative energies on banning an item of clothing worn by 0.1 per cent of the French population of adult Muslim women (or 0.003 per cent of the French population as a whole)?

2) Why did the "French internal security services" commission a study on the burqa/niqab? Is it now deemed to be a national security risk? Do French intelligence agencies have nothing better to do with their time? No other threats to deal with, apart from 2,000 Muslim women with covered faces?

Then there is the matter of the clothing itself and distinguishing between the various types. I'm no fan of the burqa or the niqab myself, and have yet to be convinced of the Islamic legal reasoning behind either garment, but I do recognise the difference between the burqa and the niqab, on the one hand, and the hijab on the other.

Does Yasmin Alibhai-Brown? In her short comment piece on the Indie's news story, and in support of the French ban, she writes:

The use of the burqa has grown like a virus across the continent. Children as young as four are now dressed in hijab.

I like Yasmin Alibhai-Brown. I admire her columns and the clarity and passion of her arguments, even if I don't always agree with her. But if even she cannot distinguish between the burqa and the hijab, two very different garments, how then can she criticise journalists and politicians, on other occasions, for misunderstanding Islam and Muslims?

Yasmin says she endorses the French approach:

I don't like the way the French state or its right-wing parties operate but sometimes there are some good unintended consequences.

I would ask her: isn't this exactly what pro-war liberal lefties said when they got into bed with George W Bush over the Iraq war and the removal of Saddam? And we all know how that turned out . . .

Mehdi Hasan is a contributing writer for the New Statesman and the co-author of Ed: The Milibands and the Making of a Labour Leader. He was the New Statesman's senior editor (politics) from 2009-12.

Joe Raedle/Getty Images
Show Hide image

“Stop treating antibiotics like sweets”: the threat we face from antibioitic resistance

Currently, 700,000 people die per year from the resistance of microbes to medicine, and it is predicted that 10 million people will die per year by 2050.

Got a cold? Take some antibiotics. Feeling under the weather? Penicillin will patch you up. Or so the common advice goes. However, unless we start to rethink our dependency on antibiotics, a death every three seconds is the threat we potentially face from evolving resistance by microorganisms to the drugs. The stark warning was issued following a review which analysed the consequences we could face from needless administering of antibiotics.

The antimicrobial resistance (AMR) review was led by economist Jim O’Neill, who was tasked by the prime minister in 2014 with investigating the impact of growing resistance. Currently, 700,000 people die per year from the resistance of microbes to medicine, and the report predicts that 10 million people will die per year by 2050. An overwhelming global expense of $100trn will be the price to pay unless incisive, collaborative action is taken.

Antimicrobial resistance (as referred to in the title of the report) is an umbrella term for the resistance developed by microorganisms to drugs specifically designed to combat the infections they cause. Microorganisms include things such as bacteria, fungi, viruses and parasites. The report especially focused on the ramifications of increased resistance of microorganisms to anitbiotics.

Many medical procedures are dependent on the effectiveness of drugs such as antibiotics: treatments for cancer patients and antibiotic prophylaxis during surgeries, for example. All could be under threat by increased resistance. The continuing rise of resistant superbugs and the impotence of antibiotics would pose “as big a risk as terrorism”. A post-antibiotic world would spell dystopia.

Bacterial microbes develop resistance through evolutionary-based natural selection. Mutations to their genetic makeup are passed on to other bacteria through an exchange of plasmid DNA. Unnecessary prescriptions by doctors and inappropriate antibiotic usage by patients (such as half-finishing a course) also contribute. Over the years, a number of bacteria and viruses have found a way to counteract antibiotics used against them: E. Coli, malaria, tuberculosis and Staphylococcus aureus, to name a few.

The report employed the consultancy firms KPMG and Rand to undertake the analyses, and O’Neill outlines 10 different measures to tackle the issue. Key areas of focus include: global campaigns to expand public awareness, the upholding of financial and economic measures by pharmaceutical companies in the development of new medicines and vaccines as alternatives, greater sanitation to prevent infections spreading, and the creation of a Global Innovation Fund which will enable collective research.

O’Neill told the BBC:

“We need to inform in different ways, all over the world, why it’s crucial we stop treating our antibiotics like sweets. If we don’t solve the problem we are heading to the dark ages; we will have a lot of people dying. We have made some pretty challenging recommendations which require everybody to get out of the comfort zone, because if we don’t then we aren’t going to be able to solve this problem.”

In the foreword of the report, O’Neill states that over 1 million people have died from developing resistance since 2014. The urgency in tackling this issue is clear, which is why he has offered an incentive to companies to develop new treatments - a reward of more than $1 billion will be given to those who bring a successful new treatment to the market.

According to the report, the cost of successful global action would equate to $40bn over the next decade, which could result in the development of 15 new antibiotics. Small cuts to health budgets and a tax on antibiotics have been proposed as ways of achieving the financial quota for drug research.

Though the report has highlighted the severity of antibiotic resistance, some believe that the full extent of the matter isn’t sufficiently explored. O’Neill mentions that there are some secondary effects which haven’t been taken into account “such as the risks in carrying out caesarean sections, hip replacements, or gut surgery”. This suggests that alternative remedies should be found for non-surgical procedures, so that antibiotics aren’t made redundant in environments where they are most needed.

Since the analysis began in 2014, new types of resistance have surfaced, including a resistance to colistin, a drug which is currently used as a last-resort. Its affordability resulted in increased use, particularly as a component of animal feed, meaning greater opportunity for superbugs to develop resistance to even our most dependable of antibiotics.

Widespread drug resistance would prove to be a big issue for many charities tackling infections around the world. Dr Grania Bridgen from Médecins Sans Frontières told the BBC that the report addresses a “broad market failure”, which is important but isn’t enough.

Despite the mixed response to the report, it has had a seal of approval from the Wellcome Trust and the Department of Health. Speaking earlier this year, Chancellor George Osborne stated this issue “is not just a health problem but an economic one, too. The cost of doing nothing, both in terms of lives lost and money wasted, is too great, and the world needs to come together to agree a common approach.”

If antibiotics are to remain potent antidotes to infectious diseases in the future, we need to put a plan in motion now.